Intrathecal Hydromorphone Versus Intrathecal Morphine for Postcesarean Delivery Analgesia: A Randomized Noninferiority Trial.

Summary

In 126 elective cesarean patients, intrathecal hydromorphone 75 µg was noninferior to morphine 150 µg for 24-hour pain (mean difference -0.46; 95% CI -1.0 to 0.1). Opioid consumption, quality of recovery (ObsQoR-11), time to first opioid, and pruritus/nausea interventions were similar, with no neonatal differences.

Key Findings

• Hydromorphone 75 µg was noninferior to morphine 150 µg for 24-hour mean NRS pain after cesarean (difference -0.46; 95% CI -1.0 to 0.1).
• No significant differences in 24-hour oral morphine equivalents, ObsQoR-11, time to first opioid, or pruritus/nausea interventions.
• Neonatal outcomes (Apgar scores) were comparable between groups.

Clinical Implications

Intrathecal hydromorphone 75 µg can substitute for morphine 150 µg for post-cesarean analgesia without compromising pain control or recovery metrics, informing formularies and protocols during drug shortages or patient-specific intolerance.

Limitations

• Primary pain outcome was recall-based at 24 hours, introducing potential recall bias.
• Moderate sample size and elective cesarean population may limit generalizability to higher-risk patients.

Future Directions

Multicenter trials to confirm findings across diverse populations, standardized dosing/monitoring protocols, and evaluation of maternal side effects, breastfeeding outcomes, and rare adverse events.